Pfizer Inc. (PFE)
Pfizer tops earnings estimates as Covid product sales beat expectations and cost cuts pay off
Pfizer reported fourth-quarter earnings and revenue that beat estimates as sales of the company's Covid products came in higher than expected and cancer drugs from Seagen boosted revenue. The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its Covid business and stock price over the last two years.
Pfizer beats fourth-quarter profit estimates on cost-cutting efforts
U.S. drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Tuesday, helped by cost-cutting efforts and better-than-expected sales of its COVID vaccine.
Pfizer Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Pfizer Inc. PFE will release its fourth-quarter financial results, before the opening bell, on Tuesday, Feb. 4, 2025.
Merck Vs. Pfizer: Which Pharmaceutical Giant Will Prevail In Q4 Earnings?
Merck & Co Inc MRK and Pfizer Inc PFE are duking it out for investor attention with fourth-quarter earnings being reported on Tuesday.
Will Non-COVID Drugs Drive PFE's Top Line in Q4 Earnings?
Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the fourth quarter.
Smaller US winter COVID wave adds pressure to Pfizer turnaround
Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could put additional pressure on Pfizer to find growth from its non-COVID treatments.
Pfizer resolves conservative challenge to diversity fellowship program
Pfizer has resolved a lawsuit by a conservative group that alleged that a fellowship program that the drugmaker established to boost the pipeline of Black, Latino and Native American people in leadership positions at the company unlawfully discriminated against white and Asian-American applicants.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer (PFE) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exploring Analyst Estimates for Pfizer (PFE) Q4 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Pfizer (PFE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
In the latest trading session, Pfizer (PFE) closed at $26.75, marking a -0.41% move from the previous day.
Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Ahead of next Tuesday's earnings release, Pfizer seems undervalued based on current price of $26.55 & valuation of $150bn. But is it madness to expect upside? Quite possibly it is. My DCF analysis suggests stock ought to be valued ~$50, but this depends on the business becoming significantly derisked by new product launches, operational efficiencies, & debt paydown. Pfizer management say its key focus areas include improving R&D productivity, expanding margins, achieving commercial excellence, and optimizing capital allocation to enhance shareholder value in 2025.
